Investors will look at the quarter and like fact that they beat estimates.

I still believe Pfizer will win the U.S. case, but you can never make any assumptions in a patent dispute.

It was mediocre. I thought we'd see more, but they flew fairly well. We'll get on a better field this afternoon.

It's the best possible win for the case, but it is not the end of the battle. The next test case will really be long-term users. Investor sentiment certainly swings probably more than it should on each individual case.

A big wildcard is how much capacity do these guys have.

This approval takes some risk out of the equation for them. If they can get the production capacity, it has the potential to be a significant drug. The big issue for Bristol is patent expirations and whether the pipeline can offset them.

We expected higher research and development costs, but the revenues were also on the weak side.

Why bother with Merck? How many venues can they (Merck) really concentrate on?

The question is how large is that market.

We have a lot of quail here, and we're going to have quail hunting this fall. It's not uncommon to flush 35 to 40 coveys a day.